Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.45 |
| ▸ | CCNK | O75909 | 10/20 | 0.45 |
| ▸ | CDK9 | P50750 | 10/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 10/20 | 0.45 |
| ▸ | CDK7 | P50613 | 8/20 | 0.45 |
| ▸ | CCNH | P51946 | 8/20 | 0.45 |
| ▸ | MNAT1 | P51948 | 7/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.44 |
| ▸ | CDK2 | P24941 | 8/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25607003 | 0.84 | GPR39 (0.56) | HRH4CCNE1CDK2 | |
| SCHEMBL13524818 | 0.83 | BRD4 (0.52) | BRD4MAPK10CCNT1CCNKCDK9 | |
| SCHEMBL13693348 | 0.83 | BRD4 (0.52) | BRD4MAPK10CCNT1CCNKCDK9 | |
| SCHEMBL19477097 | 0.83 | HRH3 (0.56) | BRD4HRH4HRH3CDK2MKNK1 | |
| SCHEMBL27109893 | 0.83 | GPR39 (0.58) | HRH4CCNE1CDK2 | |
| SCHEMBL15185737 | 0.80 | CCNK (0.51) | BRD4MAPK10CCNT1CCNKCDK9 | |
| SCHEMBL22895721 | 0.80 | CDK7 (0.49) | BRD4MAPK10CCNT1CCNKCDK9 | |
| SCHEMBL84411 | 0.80 | CDK7 (0.50) | BRD4MAPK10CCNT1CCNKCDK9 | |
| SCHEMBL28541095 | 0.80 | CDK7 (0.49) | BRD4MAPK10CCNT1CCNKCDK9 | |
| SCHEMBL15219316 | 0.79 | BRD4 (0.53) | BRD4MAPK10CCNT1CCNKCDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3442947-B1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | EPIZYME INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3442947-B1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | EPIZYME INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2021-07-01 | — | — | US | disclosed |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-20 | — | — | US | disclosed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
| WO-2017181177-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | BRD4 544/4885MAPK10 3265/4885CCNT1 1496/4885 |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | BRD4 1453/4885MAPK10 3697/4885CCNT1 898/4885 |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | BRD4 1453/4885MAPK10 3697/4885CCNT1 898/4885 |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | BRD4 544/4885MAPK10 3265/4885CCNT1 1496/4885 |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | EHMT2, EHMT1, BHMT | BRD4 1038/4885MAPK10 4166/4885CCNT1 3800/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | BRD4 544/4885MAPK10 3265/4885CCNT1 1496/4885 |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | BRD4 764/4885MAPK10 3867/4885CCNT1 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.